<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03218241</url>
  </required_header>
  <id_info>
    <org_study_id>11-501</org_study_id>
    <nct_id>NCT03218241</nct_id>
  </id_info>
  <brief_title>Single Ascending Dose Study of PRT064445, a Factor Xa (fXa) Inhibitor Antidote</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenously Administered PRT064445, a Factor Xa (fXa) Inhibitor Antidote</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Portola Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Portola Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center, double-blind, randomized, placebo-controlled, ascending, single dose
      study of PRT064445 or its matching placebo, in healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacodynamics assessments</measure>
    <time_frame>Up to 28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Plasma levels of PRT064445</measure>
    <time_frame>Up to 7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>PRT0064445 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 1 versus Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PRT064445 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 2 versus Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PRT064445 Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 3 versus Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PRT064445 Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 4 versus Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PRT064445 Dose 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 5 versus Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PRT064445</intervention_name>
    <description>Intravenous</description>
    <arm_group_label>PRT0064445 Dose 1</arm_group_label>
    <arm_group_label>PRT064445 Dose 2</arm_group_label>
    <arm_group_label>PRT064445 Dose 3</arm_group_label>
    <arm_group_label>PRT064445 Dose 4</arm_group_label>
    <arm_group_label>PRT064445 Dose 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intravenous to mimic PRT064445</description>
    <arm_group_label>PRT0064445 Dose 1</arm_group_label>
    <arm_group_label>PRT064445 Dose 2</arm_group_label>
    <arm_group_label>PRT064445 Dose 3</arm_group_label>
    <arm_group_label>PRT064445 Dose 4</arm_group_label>
    <arm_group_label>PRT064445 Dose 5</arm_group_label>
    <other_name>Placebo (for PRT064445)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy men or women between the ages of 18 and 50 years old, inclusive

          -  BMI 19-32 and weighs at least 60kgs

        Exclusion Criteria:

          -  History or symptoms of bleeding problems or thrombotic conditions

          -  Clinically significant medical history

          -  Major surgery, severe trauma, or bone fracture within 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 27, 2012</study_first_submitted>
  <study_first_submitted_qc>July 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2017</study_first_posted>
  <last_update_submitted>July 12, 2017</last_update_submitted>
  <last_update_submitted_qc>July 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy Volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antidotes</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

